12:00 AM
 | 
Oct 08, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Afatinib: Phase II data

A Korean Phase II trial in 38 evaluable patients with wild-type EGFR stage IIIb/IV NSCLC who failed 2 lines of chemotherapy showed that once-daily 40 mg oral afatinib led to a DCR of 24% with a median duration of...

Read the full 172 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >